Abstract
Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC.
Author supplied keywords
Cite
CITATION STYLE
APA
Liu, J., Agyapong, G., Misra, D., Taylor, C. D., & Hirsh, D. A. (2019). A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer. Clinical Case Reports, 7(11), 2068–2073. https://doi.org/10.1002/ccr3.2427
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free